oral irreversible FGFR1-4 inhibitor
in Ph. I-III trials for FGFR+ advanced tumors
from structure-based design
Cancer Res., Sep. 24, 2020
Taiho Pharmaceutical, Tokyo, JP
TAS-120 (futibatinib)
TAS-120 (futibatinib) is an orally available, irreversible FGFR1-4 inhibitor with a unique binding mode, targeting a unique cysteine in the P-loop of the FGFRs, rather than the Cys in the…